- Home
- CTO vs AUTL Comparison
CTO vs AUTL Comparison
Compare CTO & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTO
- AUTL
- Stock Information
- Founded
- CTO 1902
- AUTL 2014
- Country
- CTO United States
- AUTL United Kingdom
- Employees
- CTO N/A
- AUTL N/A
- Industry
- CTO Real Estate Investment Trusts
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CTO Real Estate
- AUTL Health Care
- Exchange
- CTO Nasdaq
- AUTL Nasdaq
- Market Cap
- CTO 578.8M
- AUTL 609.4M
- IPO Year
- CTO N/A
- AUTL 2018
- Fundamental
- Price
- CTO $19.45
- AUTL $2.30
- Analyst Decision
- CTO Strong Buy
- AUTL Strong Buy
- Analyst Count
- CTO 4
- AUTL 3
- Target Price
- CTO $21.50
- AUTL $10.20
- AVG Volume (30 Days)
- CTO 452.3K
- AUTL 1.6M
- Earning Date
- CTO 02-20-2025
- AUTL 11-12-2024
- Dividend Yield
- CTO 7.83%
- AUTL N/A
- EPS Growth
- CTO N/A
- AUTL N/A
- EPS
- CTO 0.61
- AUTL N/A
- Revenue
- CTO $118,662,000.00
- AUTL $10,091,000.00
- Revenue This Year
- CTO N/A
- AUTL $851.83
- Revenue Next Year
- CTO $13.12
- AUTL $264.18
- P/E Ratio
- CTO $32.11
- AUTL N/A
- Revenue Growth
- CTO 16.61
- AUTL 82.71
- 52 Week Low
- CTO $16.16
- AUTL $2.07
- 52 Week High
- CTO $21.15
- AUTL $7.37
- Technical
- Relative Strength Index (RSI)
- CTO 46.23
- AUTL 38.43
- Support Level
- CTO $19.25
- AUTL $2.17
- Resistance Level
- CTO $19.74
- AUTL $2.80
- Average True Range (ATR)
- CTO 0.41
- AUTL 0.17
- MACD
- CTO -0.03
- AUTL 0.04
- Stochastic Oscillator
- CTO 54.90
- AUTL 31.51
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a Florida-based real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.